Publications by authors named "Grogan M"
Cardiac amyloidosis represents a unique disease process characterized by amyloid fibril deposition within the myocardial extracellular space. Advances in multimodality cardiac imaging enable accurate diagnosis and facilitate prompt initiation of disease-modifying therapies. Furthermore, rapid advances in multimodality imaging have enriched understanding of the underlying pathogenesis, enhanced prognostication, and resulted in the development of imaging-based markers that reflect the amyloid burden, which is of increasing importance when assessing the response to treatment.
View Article and Find Full Text PDFBackground: The prognosis in patients with advanced cardiac amyloidosis (CA) remains poor.
Objectives: We sought to describe survival post heart transplantation (HT) in amyloid compared with non-amyloid recipients, highlight waitlist times within the new allocation system across three Organ Procurement and Transplantation Network (OPTN) regions, and describe multiorgan transplantation (MOT) in hereditary amyloidosis.
Methods: This is a retrospective review of end-stage CA patients who underwent HT at Mayo Clinic from January 2007 to December 2020.
Background: Cardiac AL and ATTR are potentially fatal cardiomyopathies. Current therapies do not address mechanisms of tissue dysfunction because these remain unknown. Our prior work focused on the amyloid plaque proteome, which may not capture tissue-wide proteomic alterations.
View Article and Find Full Text PDFArticle Synopsis
- Proprioception, a sense crucial for movement control, remains underexplored, particularly in how limb position is mapped in the brain's somatosensory cortex.
- The researchers developed a topographic variational autoencoder (topo-VAE) that, while not based on actual neural data, successfully mimics key aspects of proprioception observed in monkey movement studies.
- Their model predicts a specific geometry for how neurons encode movement across the cortex and suggests that few neurons focus on single joints, offering insights into sensory feedback applications in brain-computer interfaces and robotics.
Background: In the phase 3 randomized controlled study, ATTRibute-CM, acoramidis, a transthyretin (TTR) stabilizer, demonstrated significant efficacy on the primary endpoint. Participants with transthyretin amyloid cardiomyopathy (ATTR-CM) who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE.
View Article and Find Full Text PDFArticle Synopsis
- A study investigated the prevalence of non-sustained ventricular tachycardia (NSVT) in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) and its link to sustained ventricular arrhythmias and mortality.
- Out of 217 patients, 53% exhibited NSVT during Holter monitoring, and 5.1% experienced sustained ventricular arrhythmias during an average follow-up of 27 months.
- The presence of NSVT was associated with a higher risk of sustained ventricular arrhythmias, while all-cause mortality was similar between NSVT and non-NSVT groups, although prominent ventricular ectopy was linked to increased risks of both outcomes.
Background: The investigational monoclonal antibody PRX004 is designed to specifically target and deplete TTR amyloid. Here, we report on the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical activity of PRX004 in patients with ATTRv amyloidosis.
Methods: This global, multicentre, phase 1 trial comprised a 3 + 3 dose-escalation phase and a long-term extension (LTE) phase (NCT03336580).
Purpose: As more treatments emerge for advanced, stage IV non-small-cell lung cancer (NSCLC), oncologists have difficulty predicting functional resiliency versus functional decline throughout cancer treatment. Our study evaluates functional resilience among patients with advanced NSCLC.
Methods: Functional status was evaluated through 12 months of follow-up based on disability score using the modified EQ-5D-5L (mEQ-5D-5L) survey.
Article Synopsis
- The ATTR-ACT study aimed to assess the effectiveness of tafamidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM) over a period of up to 2.5 years, with participants either receiving tafamidis or a placebo.
- In the long-term extension study, participants who initially received tafamidis maintained their quality of life and heart failure symptoms, while those who switched from placebo to tafamidis experienced slower worsening of their conditions.
- The researchers concluded that tafamidis is beneficial in slowing down the decline in quality of life and heart failure symptoms for people with ATTR-CM, suggesting that early treatment is important.
Article Synopsis
- The study evaluates an AI model (A2E) that analyzes ECGs to predict survival in patients with cardiac amyloidosis (CA), focusing on three patient groups: light chain amyloidosis (AL), wild-type transthyretin amyloidosis (ATTRwt), and hereditary transthyretin amyloidosis (ATTRv).
- Data from 2533 CA patients were analyzed, and results showed that those with higher A2E scores had a significantly increased risk of death.
- The findings suggest that the A2E model provides useful prognostic information, helping to better assess the risk of death in patients with both AL and ATTR amyloidosis.
Article Synopsis
- Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a serious, progressive disease, and vutrisiran is a new treatment that works by reducing the production of transthyretin in the liver.
- In a double-blind trial involving 655 patients, those receiving vutrisiran had a lower risk of death and cardiovascular events compared to those on placebo, demonstrating significant efficacy.
- Vutrisiran also improved patient outcomes, showing less decline in walking distance and quality of life measurements over the study period compared to placebo.
Article Synopsis
- The ROAR-LCT clinical trial aimed to assess the feasibility of a supportive care intervention combining physical therapy and progressive muscle relaxation for older adults with advanced lung cancer.
- The study recruited 22 participants aged 60 and older with specific types of lung cancer, evaluating them through various physical and mental health measures before and after the 12-session program.
- Out of those who consented, 81.8% began the intervention, and 61.1% completed enough sessions to meet the feasibility criteria, indicating a promising approach to improve care for this population.
Article Synopsis
- Transthyretin cardiac amyloidosis (ATTR-CA) primarily impacts older adults with various chronic health issues, leading to significant physical and emotional difficulties.
- New drugs show promise in early treatment stages, prompting a need for thorough assessments of patients' functional abilities and quality of life.
- Incorporating comprehensive geriatric assessment tools into standard care can help identify early signs of frailty and improve management strategies for older ATTR-CA patients.
Article Synopsis
- Wild-type transthyretin amyloidosis (ATTRwt amyloidosis) is increasingly diagnosed in younger patients and women, despite being more common in elderly men.* -
- In a study with 1,251 patients, the average time from symptom onset to diagnosis was about 2 years, with women under 70 experiencing the longest delays.* -
- The study found that while men made up most of the patients, the proportion of women increased with age, and many patients showed significant functional impairment regardless of their age.*
Glaucophytes, an enigmatic group of freshwater algae, occupy a pivotal position within the Archaeplastida, providing insights into the early evolutionary history of plastids and their host cells. These algae possess unique plastids, known as cyanelles that retain certain ancestral features, enabling a better understanding of the plastid transition from cyanobacteria. In this study, we investigated the role of ethylene, a potent hormone used by land plants to coordinate stress responses, in the glaucophyte alga Cyanophora paradoxa.
View Article and Find Full Text PDFIntroduction: Older adults with chronic disease prioritize functional independence. We aimed to describe the feasibility of capturing functional disability and treatment toxicity among older adults with lung cancer using a longitudinal comprehensive geriatric assessment (CGA) and molecular biomarkers of aging.
Methods: This prospective study included adults ≥60 years with any newly diagnosed non-small-cell lung cancer.
Article Synopsis
- The study focuses on cardiac amyloidosis (CA) in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR), highlighting that CA commonly leads to poor outcomes for these patients.
- The researchers analyzed data from 1,426 TAVR patients using an ECG AI model to predict CA risk, discovering that 24.4% had a high probability of CA, yet only 1.2% were clinically diagnosed.
- Results showed that a high CA probability significantly correlated with increased all-cause mortality and rates of major adverse cardiovascular events, particularly heart failure hospitalizations, suggesting that these patients should undergo further diagnostic assessment for CA.
Article Synopsis
- Researchers tested an AI-enhanced ECG for detecting cardiac amyloidosis (CA) in a group of 440 diagnosed patients, compared to a control group of 6,600 who were matched by age and sex.
- The AI's performance showed an area under the curve (AUC) of 0.84, which is a decrease from an earlier study that reported an AUC of 0.91, indicating slight deterioration in accuracy.
- The AI performed well across different racial groups but struggled with Hispanic patients and conditions like left ventricular hypertrophy and left bundle branch block, highlighting the need for targeted improvements in these areas.
Article Synopsis
- - Cardiac amyloidosis is becoming recognized as a treatable type of heart failure, with effective therapies now available for its two common forms: immunoglobulin light chain amyloidosis and transthyretin (ATTR) amyloidosis.
- - Accurate treatment initiation depends on the proper identification of cardiac amyloidosis and the specific amyloid type, with noninvasive methods available for ATTR but histological confirmation still needed for many cases.
- - The review outlines the need for histological typing in certain patients and discusses various techniques for amyloid deposit typing, including mass spectrometry, immunohistochemistry, and immunoelectron microscopy, along with their pros and cons in clinical usage.
Aims: To evaluate the effect of long-term tafamidis treatment on health-related quality of life (HRQoL) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension (LTE) study.
Methods And Results: We examined change from baseline in Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) and clinical summary (KCCQ-CS) scores in patients who received tafamidis meglumine 80 mg for 30 months in ATTR-ACT and tafamidis (meglumine 80 mg or bioequivalent free acid 61 mg) for 30 months in the LTE study, and in patients who received placebo for 30 months in ATTR-ACT and tafamidis for 30 months in the LTE study. In ATTR-ACT, 176 and 177 patients were randomized to tafamidis 80 mg and placebo, respectively.
Article Synopsis
- HELIOS-A was a Phase 3 study examining the effects of vutrisiran, an RNA interference therapy, on cardiac health in patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy.
- Patients were divided into two groups: one receiving vutrisiran every three months and another receiving the reference treatment, patisiran, every three weeks.
- Results indicated that vutrisiran was linked to a significant reduction in NT-proBNP levels and other positive changes in heart-related metrics without increasing cardiac adverse events compared to the external placebo.
Article Synopsis
- Transthyretin amyloidosis (ATTR amyloidosis) has two forms: wild-type (ATTRwt) and hereditary (ATTRv), with over 130 identified genetic variants affecting patient symptoms.
- This analysis looked at four less common genetic variants (F64L, I68L, I107V, S77Y) in symptomatic patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS) to better understand their demographic and clinical characteristics.
- Findings revealed that most participants were older males, with distinct symptoms where F64L, I107V, and S77Y had more neurological issues, while I68L showed significant heart problems, highlighting the need for thorough patient evaluations across